Clinical neurorestorative progress in Alzheimer’s disease

Liyan Qiao1
Hongyun Huang2,3
Dafin F Muresanu4,5

1Department of Neurology, Tsinghua University Yuquan Hospital, 2Beijing Rehabilitation Hospital of Capital Medical University, 3Beijing Hongtianji Neuroscience Academy, Beijing, People’s Republic of China; 4Department of Clinical Neurosciences, Iuliu Haţieganu University of Medicine and Pharmacy, RoNeuro Institute for Neurological Research and Diagnosis, Cluj-Napoca, Romania

Abstract: Alzheimer’s disease (AD) is the most prevalent type of dementia, and its neuropathology is characterized by the deposition of insoluble β-amyloid peptides and intracellular neurofibrillary tangles and the loss of diverse neurons. Although much is known about the neurobiology of AD, few treatments are available to arrest or slow the illness. There is an urgent need for novel therapeutic approaches for AD. We reviewed the recent improvements in the neurorestoratology strategies for AD, including medicine, bioengineering and neuromodulation and clinical cell therapy. We emphasized that cell therapy may be a promising treatment for AD.

Keywords: Alzheimer’s disease, neurorestoratology, cell therapy, medicine

Introduction

Alzheimer’s disease (AD) is the most prevalent type of dementia, and its neuropathology is characterized by deposition of insoluble β-amyloid (Aβ) peptides, intracellular neurofibrillary tangles, amyloid angiopathy, age-related brain atrophy, synaptic pathology, white matter rarefaction, granulovacuolar degeneration, neuron loss, and neuroinflammation.1 Currently, it is estimated that 5.2 million Americans of all ages have AD. Among them, 5 million people are aged 65 years of age.2

With the exception of the rare cases of AD caused by known genetic mutations, AD, similar to other common chronic diseases, develops as a result of multiple factors rather than a single cause. The known risk factors for AD include age, family history, presence of the apolipoprotein (Apo)E ε4 gene, mild cognitive impairment, traumatic brain injury, cardiovascular disease risk factors, lack of social and cognitive engagement, and lower education level.1,2

Abnormal accumulation of Aβ peptide is widely believed to be the underlying mechanism of pathologic and clinical changes seen in AD.1,3 Aβ appears earliest in the cerebral neocortex, prior to onset of symptoms, and reaches the cerebellar cortex in advanced clinical disease.4 Although Aβ plaques may play a key role in AD pathogenesis, the severity of cognitive impairment correlates best with the burden of neocortical neurofibrillary tangles.3 Cholinergic dysfunction in the basal and rostral forebrain is associated with even early cognitive impairments observed in AD.6 In addition to abnormal accumulation of the Aβ peptide, the formation of neurofibrillary tangles, and the degeneration of the cholinergic pathway, AD has also been associated with environmental and genetic factors, mitochondrial dysfunction, vascular factors, immune system dysfunction, and infectious agents. Neurovascular dysfunction plays an essential role in this multifactorial pattern. The neurovascular unit encompasses
neurons, interneurons, astrocytes, smooth muscle cells, pericytes, endothelial cells, and the extracellular matrix.7 A broad spectrum of insults to the neurovascular unit, such as blood–brain barrier break down, cerebral amyloid angiopathy, loss or abnormal cholinergic innervation of blood vessels, arterial hypercontractility, atherosclerosis, vascular anatomical defects, mitochondrial abnormalities of the endothelial cells, and degeneration of pericytes, has been implicated.8,9

The treatment of AD mainly includes nonpharmacologic and pharmacologic therapies. None of the treatments available for AD, except for neurorestorative strategies, have been shown to slow or stop the malfunction and death of neurons in the brain that cause AD symptoms. Here, we review the recent clinical progress of neurorestorative strategies.

Clinical progress of neurorestorative strategies

Medicine and factors

Currently, no single molecule has been approved for the treatment of AD since the advent of cholinesterase inhibitors and memantine. However, potential neurorestorative treatments that have been tested in AD patients are emerging.

γ-secretase inhibitors (GSIs) and modulators

γ-secretase cleaves amyloid precursor proteins (APPs) to release Aβ peptides, which play a causative role in the pathogenesis of AD. GSIs have been developed and used for clinical studies. Studies in animal models of AD have indicated that GSIs administered by the oral route are able to lower Aβ concentrations. However, GSIs cause nondiscriminatory inhibition of Notch (a transmembrane receptor involved in regulating cell-fate decisions) signaling, overall APP processing, and other substrate cleavages. These findings have called for the development of disease-modifying agents called γ-secretase modulators, which target γ-secretase activity and lower Aβ42 production without blocking the overall processing of γ-secretase substrates. Animal studies of this generation of γ-secretase modulators have shown encouraging preclinical profiles.10,11

Two large Phase III clinical trials of semagacestat (LY-450139) in patients with mild to moderate AD were prematurely interrupted due to the observation of detrimental effects on cognition and functionality in patients receiving the drug compared with those receiving placebo.12 Two large Phase III studies of tarenflurbil (r-flurbiprofen), a putative γ-secretase modulator, in patients with mild AD were also completely negative. The failures were ascribed to the inhibition of the cleavage of Notch, and low potency and brain penetration.13,14

Immunology

Active and passive immunotherapy targeting either Aβ or tau has been successful in repeated AD model animal trials.15,16 In the last decade, an increased number of clinical trials for AD immunotherapy have started, failed, and are continuing to be pursued.17 AN-1792 was the first drug to actively immunize humans with Aβ peptide. Approximately 5% of treated patients presented with meningoencephalitis, which halted its Phase II trial prematurely. It is likely that the severe inflammatory symptoms from AN-1792 related significantly to the immunological adjuvant.18 Bapineuzumab (AAB-001) is a humanized mouse monoclonal antibody to the N-terminal portion of Aβ. Its Phase II trial has shown increased side effects, including vasogenic edema of the brain, in ApoEε4 carriers, but evidence suggestive of a benefit has also been found, particularly in noncarriers of the ApoE ε4 allele. A different humanized mouse monoclonal antibody to the midportion of Aβ, solanezumab (LY2062430), has been shown to clear soluble Aβ, accompanied by biomarker changes in cerebrospinal fluid (CSF) in a Phase II trial.

Pilot studies of human intravenous immunoglobulin (IVIG) resulted in the stabilization of cognitive functioning in patients with mild to moderate AD. The putative mechanism for IVIG involves low levels of polyclonal anti-Aβ antibody that possibly modify the immune response. However, the subsequent Phase III trial found no evidence for slowing of AD progression. These disappointing results have reduced enthusiasm for IVIG as a possible treatment for AD.19

Anti-inflammatory drugs

Long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs) reduces the risk of developing AD and delays its onset, as shown by epidemiological studies. In addition, a subset of NSAIDs, such as ibuprofen, indomethacin, and flurbiprofen, may have direct Aβ-lowering properties in cell cultures as well as in transgenic models of AD-like amyloidosis.20 However, treatment for 1 to 3 years with naproxen or celecoxib did not protect against cognitive decline in older adults with a family history of AD.21

Neurotrophic factors (NTFs)

Based on current scientific knowledge, treatment with NTFs would be a desirable intervention for brain diseases with a complex pathology, such as dementia. Unlike the classical single-target molecules used for current therapies, NTFs
allow for designing treatment strategies based on multimodal activity (Figure 1).

Cerebrolysin® is a parenterally administered neuropeptide preparation that contains active fragments of some important NTFs and has displayed activity closely matching that of endogenous NTFs in preclinical research models of neurological disorders; it exerts neuromodulatory therapeutic effects, including pleiotropic neuroprotective effects (such as antiapoptotic, anti-inflammatory, and antioxidative activity and the reduction of toxic protein aggregates) and neurorestorative effects (including the stimulation of neurogenesis, neuronal sprouting and synaptogenesis, oligodendrogenesis, and neurite remodeling). Cerebrolysin reduces toxic protein aggregation as well as activation of proapoptotic genes by modulating key regulatory elements of the neurotrophic signaling pathway, namely glycogen synthase kinase-3β (GSK3β) and cyclin-dependent kinase-5 (CDK5). Cerebrolysin has been shown to protect brain tissue against amyloid plaque formation by modifying APP maturation, a process regulated by these phosphorylating enzymes. By modulating the activity of these enzymes, Cerebrolysin reduces the cellular transport of APP to synaptic sites, thus lowering the titer of Aβ peptides released into the extracellular matrix, which results in reduced formation of amyloid plaques. Treatment with Cerebrolysin also results in a significant decrease in the levels of tau tangles, by modulating activity of the same enzymes.

Several clinical trials have been performed to investigate the safety and efficacy of Cerebrolysin in patients suffering from mild to moderately severe AD. Clinical data have strongly shown that Cerebrolysin is an effective therapeutic option for patients diagnosed with AD. Most of the randomized, double-blind, placebo-controlled trials have shown significant improvement in cognitive, behavioral, functional, and global domains after treatment with Cerebrolysin. These effects were largely maintained over several months, indicating a long-term beneficial influence of Cerebrolysin on the disease. Due to the drug’s multimodal activity and pleiotropic neuroprotective effects, which target distinct molecular pathways in the pathologic cascade, treatment with Cerebrolysin

Figure 1 Mode of action of the pleiotropic multimodal drug Cerebrolysin® in AD.

Notes: (A) Both genetic and environmental factors contribute to activation of CDK5 and GSK3β signaling pathways. Both kinases are involved in promoting neurofibrillary and Aβ neurodegeneration pathology. (B) Cerebrolysin treatment modulates the activity of both CDK5 and GSK3β kinases, leading to decreased APP maturation, decreased APP cellular transport to synaptic sites, and decreased tau phosphorylation.

Abbreviations: Aβ, β-amyloid; AD, Alzheimer’s disease; APP, amyloid precursor protein; CDK5, cyclin-dependent kinase-5; GSK, glycogen synthase kinase.
goes far beyond pure symptomatic improvement, suggesting a potential delay in disease progression.\textsuperscript{30–32}

It is well known that there are close interactions between AD and vascular dementia; in the majority of cases, it is difficult to determine the difference between these two types of dementia.\textsuperscript{33,34} Coexistence of degenerative and vascular pathology has both additive and synergistic effects on dementia progress. Cerebroslysin also has beneficial effects on cognitive and global function in elderly patients with vascular dementia of mild to moderate severity, as shown in a recent Cochrane review.\textsuperscript{35}

\textbf{Bioengineering}

Genetically modified neural stem/progenitor cells (NSCs) and mesenchymal stromal cells (MSCs) that stably express and secrete A\textsubscript{β}-degrading enzyme, human choline acetyltransferase, and nerve growth factor (NGF) gene have been tested in transgenic mouse models of AD. These approaches was shown to enhance synaptic plasticity, elevate acetylcholine level, and improve the cognitive function in AD animal models.\textsuperscript{36–43} Tuszyński et al\textsuperscript{44} performed a Phase I trial by implanting autologous fibroblasts genetically modified to express human NGF into the forebrain of eight individuals with mild AD. No long-term adverse effects of NGF occurred. A cognitive evaluation suggested improvement, and robust growth responses to NGF were observed in one brain autopsy. Injections of DNA coding for brain-derived neurotrophic factor (BDNF) has been the subject of a Phase I experiment.\textsuperscript{45} As NGF or BDNF are not the sole candidates as a possible contributor to brain homeostasis among 50 different trophic factors in the brain, their neuroprotective effect are still being considered.

\textbf{Clinical cell therapy}

Cortical cholinergic loss is strongly associated with the reduction of progenitors.\textsuperscript{46} However, viable precursor cells do remain in AD and aged normal control brain specimens and can be induced to differentiate.\textsuperscript{47} Lower stem cell factor plasma levels were found in AD patients.\textsuperscript{48} These results raise the possibility of stimulation of inherent precursor cells of aged individuals or AD patients to replace neurons lost in aging and/or neurodegeneration.\textsuperscript{49}

Sanchez-Ramos et al\textsuperscript{50} investigated the effects of a 5-day schedule of granulocyte colony stimulating factor (G-CSF) administration in eight patients with mild to moderate stage AD and found it was tolerated and safe, and it improved cognition. A South Korea group conducted a Phase I trial in nine patients with mild to moderate AD, using umbilical cord stromal cells. The cells were injected bilaterally in the hippocampus and in the right precuneus. There were no serious adverse events. The Alzheimer’s Disease Assessment Scale-Cognitive subscale (ADAS-cog) suggested possible improvements in two patients; seven patients showed cognitive decline at 1 month and 3 months. Pittsburgh compound B (PiB) positron emission tomography (PET) scans showed a decreased PiB retention ratio in four patients, but five patients showed an increased PiB retention ratio at 1 month and 3 months. Among 12 Neuropsychiatric Inventory (NPI) items, the scores in ten items decreased at 3 months and the scores in two items increased at 3 months compared with baseline.\textsuperscript{50}

\textbf{Neuromodulation}

\textbf{Deep brain stimulation (DBS)}

By targeting specific structures within known memory circuits, including the entorhinal, and hippocampal areas, and activating the brain’s default mode network, DBS can have effects in AD patients and is therefore a potentially promising avenue for novel dementia treatments. It has been shown that no complications occurred and that the stimulation was perfectly tolerated, after DBS treatment in AD patients. After 1 year of stimulation, the memory scores were either stabilized or possible improved compared with baseline, in pilot studies.\textsuperscript{51,52}

\textbf{Repetitive transcranial magnetic stimulation (rTMS)}

rTMS is a noninvasive tool for modulating cortical activity and a potential therapy choice for AD. However, no recommendation for rTMS was suggested in AD patients.\textsuperscript{53} Nevertheless, high-frequency rTMS seems to have better effects on improving cognitive function in AD patients compared with low-frequency rTMS, especially in combination with cognitive therapy.\textsuperscript{54,55}

\textbf{Discussion}

\textbf{The rationality for cell therapy in AD}

The rationale for cell therapy in AD is based on the following findings:

Impaired neurogenesis in the subventricular zone has been found in early AD.\textsuperscript{56,57} A\textsubscript{β} impairs the proliferation and neuronal differentiation of neuronal precursor cells and contributes to the depletion of neurons and cognitive impairment in AD.\textsuperscript{58} APP, especially APP possessing the protease inhibitor domain, regulates the growth of neuronal precursor cells during development of the nervous system.\textsuperscript{59}
Either a wild-type or a familial AD (FAD) mutant PS-1 transgene can reduce the number of neural progenitors in the dentate gyrus. However, the wild-type, but not the FAD mutant, PS-1 promoted the survival and differentiation of progenitors, leading to the generation of more immature granule cell neurons in PS-1 wild-type-expressing animals. As well, some evidence shows compensatory increase in neurogenesis after PS-1 mutation, which represents FAD pathogenesis.

Finally, in separate work, the deafferented hippocampus provided proper microenvironment for the survival and neuronal differentiation of neural progenitors.

The mechanism of cell therapy in AD
Cell types that have been used in AD include NSCs, MSCs, embryonic stem cells (ESCs), and induced pluripotent stem cells. These cell types have been shown to be beneficial for increasing neurogenesis and neuronal differentiation, enhancing Aβ clearance, inhibiting cell death, recovering acetylcholine levels, and improving clinical symptoms, including memory and visuospatial impairment (Figure 2).

Increased neurogenesis
MSCs increase hippocampal neurogenesis, neuronal differentiation, and the formation of neurites. These outcomes may be achieved by enhancing the Wnt signaling pathway in AD models.

Inhibition of cell apoptosis and cell death
MSCs can inhibit cell apoptosis and cell death caused by either Aβ or tau, which are accompanied by memory improvement.

Clearance protein aggregates
MSCs have capacity to clear Aβ but not tau. The possible mechanism for clearing Aβ is by enhancing autophagy function.

Increased trophic factors
Human adipose tissue-derived MSCs could enhance the concentrations of BDNF and NGF, which would be accompanied by an improvement in cognitive function. Another group showed that MSCs, via intravenous or intracerebral transplantation, significantly rescued memory deficit and neuropathology, by upregulating cytokine interleukin (IL)-10 and vascular endothelial growth factor (VEGF).

Induction of acetylcholine production in AD
Increasing the acetylcholine level is crucial for current therapy methods for AD. In neurorestorative treatment, two methods can be used to achieve the goal of increasing the acetylcholine level: bioengineering and cell therapy. As mentioned above, the acetylcholine level could be increased by gene expression via a vector. For the latter, several cell types have been shown to have the potential to differentiate into cholinergic cell phenotypes. Transplanted NSCs were

Figure 2 The potential mechanism of cell therapy in AD.
Notes: In AD models, cell therapy has been shown to be beneficial for increasing neurogenesis and neuronal differentiation, enhancing Aβ clearance, inhibiting cell death, recovering acetylcholine levels, and improving cognitive impairment. The gray area shows the basic pathophysiologic changes in AD, and the red area represents the possible restoring mechanism of cell therapy in AD.
Abbreviations: Aβ, β-amyloid; AD, Alzheimer disease.
shown to differentiate into cholinergic neurons in a rat AD model. Transplantation of mouse ESC-derived neuronal precursor cells, following commitment to a cholinergic cell phenotype, were able to promote behavioral recovery in a rodent model of AD. No tumors were formatted, which indicated that ESCs may be safe for transplantation.

Neuronal precursors with cholinergic neuron phenotype derived from human induced pluripotent stem cells survived in APP mouse hippocampus and improved their spatial memory loss. Induced pluripotent stem cells derived from dermal fibroblasts of AD patients and differentiated into cholinergic neurons might be a promising novel tool for disease modeling and drug discovery for the sporadic form of AD and FAD. In one study, human adipose tissue-derived MSCs were intravenously or intracerebroventricularly transplanted into the brains of 18-month-old mice. Transplantation improved both locomotor activity and cognitive function in the aged animals, in parallel with recovery of acetylcholine levels in brain tissues.

**Inducing endogenous cell in AD therapy**

AD subjects have significantly fewer viable precursor cells in the hippocampus compared with age-matched normal control subjects. However, viable precursor cells remaining in AD and aged normal control brain specimens can be induced to differentiate. These endogenous precursor cells can be induced to show neuroprotective effects by chemical compounds and stimulating factors, such as allopregnanolone (Apt), fluoxetine, G-CSF, AMD3100, stromal cell-derived factor-1a (SDF-1α), and others.

Recent studies have proposed that chronic treatment with antidepressants increases neurogenesis in the adult hippocampus. Chang et al showed the dose-dependent effects of fluoxetine, a common antidepressant, on the proliferation and neural differentiation of fetal derived NSCs. Fluoxetine, even at nanomolar concentrations, stimulated proliferation and differentiation of NSCs. In addition, fluoxetine has protective effects against cell death induced by Aβ. Chadwick et al showed amitriptyline, another common antidepressant, mediated cognitive enhancement in aged AD mice that was associated with neurogenesis and neurotrophic activity.

Even though the distribution of G-CSF and G-CSF receptor has not been shown to substantially differ between AD and control brains, even in the hippocampus, there are studies suggesting that G-CSF can be used in AD treatment. G-CSF application was shown to improve memory and neurobehavior in an Aβ-induced experimental model of AD. G-CSF has also been shown to decrease the brain amyloid burden.

SDF-1α is an effective adjuvant in inducing migration of endogenous bone marrow-derived hematopoietic progenitor cells, which are mobilized by G-CSF, into the brain, suggesting that these two molecules can act synergistically to produce a therapeutic effect in AD.

GLP-1 is a growth factor that has neuroprotective properties. GLP1 receptors are present on neuronal progenitor cells, and the GLP1 analogue liraglutide was shown to increase cell proliferation and differentiation into neurons in an AD mouse model.

**The therapy time for AD**

MSCs can promote the reduction of Aβ and the improvement of synaptic transmission, both in AD mice and in predementia AD mice, which indicates that MSCs may exert their effects in different stages of AD.

**The aging effect**

AD is common in the elderly, and it is not known whether transplanted cells can work in the aging environment. Human adipose tissue-derived MSCs were intravenously or intracerebroventricularly transplanted into the brains of 18-month-old mice. Transplantation improved both locomotor activity and cognitive function in the aged animals, in parallel with recovery of acetylcholine levels in brain tissues through enhanced concentrations of BDNF and NGF.

**Conclusion**

Although much is known about the neurobiology of dementia and AD, very few conventional therapies are available to arrest or slow the illness. There is an urgent need for novel therapeutic approaches for AD. Translating neurorestorative strategies with positive preclinical results for AD into clinical studies has allowed patients to receive clinical neurorestoration to a certain extent, via medicine/factors, cell therapy, neuroromodulation, neurorehabilitation and combined therapies. Cell-based neurorestorative strategies are promising for AD. To gain better neurorestorative effect, earlier interventional neurorestorative strategies for AD should be recommended because dementia and other clinical presentations occur well after the pathological findings in AD. In the future, there should be greater encouragement to translate effective preclinical neurorestorative strategies to clinic practice as quickly as possible.

**Disclosure**

The authors report no conflicts of interest in this work.
References


